Best FDA-Approved GLP-1 on SmithRx Formulary (2026)

Affiliate disclosure: The RX Index may earn a commission from some links on this page. It never changes what we verify or what we recommend. SmithRx does not pay us. Neither do the drug makers. By The RX Index Editorial Team · Last verified: August 17, 2026 Scope: This page compares public FDA and plan documents. It cannot tell you which medicine is safe for you or quote your benefit. Your clinician, FDA labeling, and your plan documents control.

For most people searching for the best FDA-approved GLP-1 on SmithRx formulary, the first drug to ask about is Zepbound — when the main goal is weight loss, diabetes is not the condition being treated, no other labeled condition pushes the choice toward Wegovy, the employer plan covers weight-loss medicine, and the clinician agrees Zepbound fits.

That answer changes in six situations, and we'll name every one of them below.

Here's the part almost nobody tells you. We checked one live SmithRx Essential employer-plan lookup and its current August 2026 files. The prior-authorization file names newer products including Foundayo and Wegovy HD. A separate preventive-medication file names several diabetes GLP-1 products. The step-therapy file names none of the GLP-1 products we checked.

So “which GLP-1 is on the better SmithRx tier?” does not have one safe public answer for every member. The PA, preventive, and step files show how one employer plan manages drugs. They do not quote your member price, prove that weight-loss medicine is an included benefit, or settle the tier for every SmithRx plan.

Preventive-list status still matters, but it does not decide your bill by itself. Your plan type, benefit document, deductible, exact drug form, and program rules finish the answer.

We'll show you the current files, the preventive-list catch, and the four things that decide your real answer.

Best for you if / not for you if

This page is for you if:

• Your employer switched to SmithRx, or your card says SmithRx, and you want to know which FDA-approved GLP-1 to aim for
• Your pharmacy just rejected your GLP-1 and you don't know why
• You want to walk into your next doctor visit knowing what your plan actually allows
• You want to know what to do if the answer is no

This page is not for you if:

• You want a compounded GLP-1. Compounded drugs are not FDA-approved. FDA does not verify their safety, effectiveness, or quality before marketing. We keep compounded treatment and FDA-approved formulary treatment completely separate. See our compounded GLP-1 guide instead.
• You want us to promise your copay. We can't see the member-level result tied to your plan, so we won't make one up.
• You want a dose. That's your doctor's call, not ours.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

What we actually verified

Checked August 17, 2026. Primary sources and plan documents opened and read. 1. One live SmithRx Essential employer-plan lookup and its current files: prior authorization effective August 2026, preventive medications effective August 2026, and step therapy last updated July 2026. 2. Two real SmithRx client plan documents: Sana Benefits, updated July 16, 2026, and Cass County's 2026 plan Q&A. They publish different Tier 2 prices and different deductible rules. 3. Sana's February 2026 preventive-medication help page, which explains the PREV and ACA markings used with its SmithRx formulary. 4. SmithRx's Weight Management Program page and SmithRx member information. 5. Current FDA prescribing information for Zepbound, Wegovy, Foundayo, Mounjaro, Ozempic injection, Rybelsus and Ozempic tablets, and Saxenda. 6. The published SURMOUNT-5 head-to-head trial of tirzepatide versus semaglutide. 7. IRS Notice 2019-45 and IRS Publication 969 for the high-deductible preventive-care rules. 8. Ro's and Sesame's official pricing and program pages, checked August 17, 2026. What we could not verify, and won't pretend to: your coverage, your copay, a SmithRx-wide GLP-1 tier, whether your employer excludes weight-loss drugs, whether the word “WEGOVY” in a plan file covers every Wegovy form, or whether your prior authorization gets approved. We'll show you exactly where each of those lives.

The current SmithRx files are plan-specific. The tables below summarize the findings so readers can compare what each file proves without mistaking one plan's list for a national promise.

What is the best FDA-approved GLP-1 on SmithRx formulary?

For most adults whose goal is weight loss, Zepbound is the strongest FDA-approved GLP-1 to ask about first — when the plan covers weight-loss medicine and the clinician agrees it fits. In the SURMOUNT-5 head-to-head trial, adults with obesity, or overweight plus an obesity-related condition, and no diabetes had about 20.2% average weight loss at 72 weeks with tirzepatide versus about 13.7% with semaglutide dosed at 1.7 or 2.4 mg. The trial was funded by Eli Lilly, the maker of Zepbound. Six situations change that answer.

Now the six.

Safety stop: Trial results and coverage are not the whole decision. Zepbound, Wegovy, Foundayo, Mounjaro, Ozempic, Rybelsus/Ozempic tablets, and Saxenda each carry a boxed warning about thyroid C-cell tumors seen in animals; it is unknown whether these medicines cause those tumors in people. They are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Each product has other warnings and contraindications. Read the current Medication Guide and talk with your clinician before treatment.

Read that last row twice. It's the biggest fork on this whole page, and we come back to it.

Why “best” here means “best first question,” not a prescription

We're not writing you a prescription. We can't. Here's what “best” honestly means on a page like this:

• A drug can have great trial results and still be excluded by your employer's plan. Then the results don't matter.
• A drug can be on the preferred tier and still be medically wrong for you.
• A drug can be covered and still cost you a lot, because “covered” and “cheap” are not the same word.
• A drug can be FDA-approved but not for your goal. That's the diabetes-versus-weight fork.

Your doctor decides what's medically right. Your plan decides what it pays for. This page gets you the facts to walk into both conversations ready.

Four things decide your real answer

1. What condition you're treating. Weight management, type 2 diabetes, established cardiovascular disease, obstructive sleep apnea, or noncirrhotic MASH with F2 to F3 fibrosis — different labels, different shortlists.
2. Your employer's plan. Not SmithRx generally. Yours.
3. The exact form and strength. “Wegovy” is not one item. More on that below, and it trips up almost everybody.
4. Your medical history and what your clinician says.

→ Do this first: sign in to your SmithRx member account and look up your exact drug by brand, dosage form, and strength. Your plan result can flip this whole page. We wrote a 10-minute walkthrough further down.

Which FDA-approved GLP-1s are on the SmithRx formulary in 2026?

There is no single current drug list that answers this for every SmithRx member. In one live Essential employer plan, the August prior-authorization file names Foundayo, Wegovy, Wegovy HD, Zepbound, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, and liraglutide. A separate preventive file names several diabetes GLP-1 products. Those files show plan management status — not a SmithRx-wide tier, copay, or coverage promise.

What one live Essential plan shows now

This is a status map, not a coverage promise.

The same live lookup warns that its drug file does not guarantee coverage, that a benefit document may exclude drugs listed there, and that the list can change.

Four details you see only when the files are put side by side

1. A utilization-management file is not a tier or coverage promise. A drug can appear in a PA or preventive file while the controlling benefit document excludes the category or the member still owes a deductible.

2. Current files can move faster than broad public summaries. Foundayo was approved in April 2026 and Wegovy HD in March 2026. Both appear in one live plan's August prior-authorization file.

3. No GLP-1 appears in one current plan's July step-therapy file, but a separate weight-management program can still require a step-wise path. The paperwork can live outside the formulary.

4. One word can hide more than one product. The current PA file says “WEGOVY,” plus a separate “WEGOVY HD.” FDA labeling now covers standard injection, the 7.2 mg Wegovy HD injection, and tablets. You still need an exact form search.

Why you can't find your drug in the document

This is not you being bad at PDFs. The documents are genuinely hard to search.

GLP-1 products can sit under anti-obesity, incretin mimetic, diabetes, or insulin-combination headings. Tirzepatide can show up as Zepbound in the weight-management lane and Mounjaro in the diabetes lane. Semaglutide can show up as Wegovy, Ozempic, Rybelsus, or Ozempic tablets, depending on the form and approved use.

Search tip that actually works: use the live plan search first. Search the brand in all caps, then search the active ingredient. If the result says only “WEGOVY” or “OZEMPIC,” call the member number and ask the rep to read back the dosage form, strength, tier, PA rule, and benefit status.

### Find your row without giving away private data Open the SmithRx member page, sign in through your plan, and search the exact product. Do not enter your password, member ID, prescription number, or medical records into any third-party quiz or public form.

Why can't one public list tell you what you'll pay?

SmithRx is a pharmacy benefit manager. It processes the prescription side of employer plans. The formulary and utilization-management files show how drugs are organized and what rules may apply. Your employer's benefit design and controlling plan documents decide whether a category is included and how you share the cost.

That distinction is the whole ballgame, so let's slow down on it.

• Your employer or plan sponsor chooses the benefit design.
• Your plan documents hold the covered benefit categories, exclusions, deductible, copays, and coinsurance.
• The formulary lookup shows drug tiers and requirements for that plan's setup.
• Your member portal and controlling benefit documents settle your own coverage question.

There isn't one public SmithRx answer waiting for every member. The live lookup is keyed to a group and plan. The same PBM can sit behind two employers with different Tier 2 copays and different high-deductible rules.

That's why every article telling you to “just check your formulary” fails. There isn't one answer to check. There's yours.

The sentence that catches everyone

One SmithRx client publishes it plainly in its member help center: some drugs, like weight-loss or hair-loss drugs, may be listed on the formulary but excluded from the plan by the Summary Plan Description. The formulary does not guarantee coverage.

Cass County's 2026 document makes the same split another way: its Essential lookup shows tier and requirements, but it says the tool does not answer whether a drug benefit category is covered.

Being listed helps. It is not a coverage promise. If a drug is not listed, SmithRx says a prescriber can request a formulary exception with supporting medical documentation.

We put that in bold because it's the single most common reason a reader ends up confused and angry at the pharmacy counter. The drug was right there on the list. The claim still rejected. Nothing was broken. The list and the benefit are two different layers.

Our honest limit

We cannot see the member-level result tied to your plan. So we can't promise your copay, and we can't promise your prior authorization gets approved. Any general page that gives every SmithRx member one guaranteed answer is guessing. What we can do is show you what the current PA, preventive, and step files prove, explain what PREV and a preventive listing can and cannot mean, and hand you the exact steps and scripts to get your own number.

Why we don't run member testimonials on this page

We looked. There is no verified, attributable quote from a SmithRx member about GLP-1 coverage that we're willing to publish, and we won't invent one.

There's also a better reason to skip them. A testimonial cannot tell you whether your drug is covered. Someone saying “SmithRx covered my Zepbound” tells you about their employer's plan, not yours. Putting that next to a coverage question would actively mislead you.

What we can point to instead, all checkable:

• A real $30 Tier 2 example. Sana's SmithRx PPO plans publish a $30 retail Tier 2 copay and $60 for a three-month mail-order fill.
• A real $25 Tier 2 example. Cass County publishes $25 for a one-month Tier 2 fill on its copay plan.
• Two different high-deductible answers. Sana says members pay the full cost of non-preventive medicine before the deductible. Cass County says members pay full prescription cost before the deductible, then 20% coinsurance until the out-of-pocket maximum.

Same PBM. Same year. Different money.

Why a covered GLP-1 can still cost you full price

A current preventive-medication file from one live SmithRx Essential plan includes diabetes GLP-1 products such as Mounjaro, Ozempic, Rybelsus, liraglutide, Trulicity, Soliqua, and Xultophy. The weight-management brands Zepbound, Wegovy, Wegovy HD, Foundayo, and Saxenda were not located in that preventive file. On a high-deductible plan, that difference may change when plan payment starts — but it does not guarantee coverage, a copay, or a pre-deductible benefit.

This is the part of the page we'd want you to read if you only read one part.

The federal rule behind the diabetes line

In 2019 the IRS published a limited safe harbor for certain care used to prevent a diagnosed chronic condition from getting worse. IRS Notice 2019-45 names “insulin and other glucose lowering agents” for people diagnosed with diabetes.

That helps explain why diabetes drugs can appear on a plan's preventive file. It does not prove why SmithRx placed any one drug there, and it does not make the benefit automatic.

There is another detail people miss. IRS Publication 969 also lists obesity weight-loss programs as an example of preventive care an HDHP may cover before the deductible. A weight-loss program is not the same thing as every weight-loss prescription. Neither IRS source lets a public page promise that Zepbound, Wegovy, or Foundayo will be paid before your deductible.

The safe answer is the plan answer: check the current preventive file, then read your benefit document or ask the plan how the exact drug applies to the deductible.

The same active ingredient, two benefit paths

Tirzepatide is the active ingredient inside both Mounjaro and Zepbound.

In the one live plan file we checked, Mounjaro appears on the preventive list. Zepbound does not.

Same active ingredient. Different brand, different FDA-approved use, different benefit lane — and potentially a very different bill.

Semaglutide creates the same fork: Ozempic and Rybelsus are diabetes products, while Wegovy is the weight-management brand.

Three things this does not mean

Please don't walk away with the wrong version of this.

1. It doesn't mean your plan does it. The federal rule allows certain pre-deductible preventive coverage. Your plan documents decide what your plan does.
2. It doesn't mean the drug is covered. Preventive treatment and benefit inclusion are separate questions.
3. The SmithRx file has a Connect footnote. It says medications are not subject to that preventive list when a member is using the SmithRx Connect program. The program you're in can change whether the preventive file applies.

### Ask one question that clears up the whole section “For [exact drug and form], is it on my plan's preventive-medication list, and does my deductible apply before the plan pays? Please read the answer from my benefit document, not only the formulary.”

Is Zepbound or Wegovy better if SmithRx covers both?

For adults with obesity, or overweight plus an obesity-related condition, and no diabetes, the direct SURMOUNT-5 trial favored tirzepatide: about 20.2% average weight loss versus about 13.7% with semaglutide at 72 weeks. The semaglutide arm used maximum tolerated doses of 1.7 or 2.4 mg. It did not test Wegovy HD 7.2 mg or Wegovy tablets. Wegovy also carries FDA-labeled uses that Zepbound does not.

If both are covered on the same cost terms, the choice comes down to the direct evidence, the exact Wegovy product, the labeled condition that fits you, safety, and your clinician's judgment.

What the head-to-head trial actually found

The trial is called SURMOUNT-5. Here's the honest version:

• Who: adults with obesity, or overweight plus at least one obesity-related condition, without diabetes
• How long: 72 weeks
• What was compared: tirzepatide at a maximum tolerated dose of 10 or 15 mg versus semaglutide at a maximum tolerated dose of 1.7 or 2.4 mg
• Result: roughly 20.2% average weight change with tirzepatide versus roughly 13.7% with semaglutide
• Sponsor: Eli Lilly, the maker of tirzepatide products

That's a real, direct, head-to-head result. It's the strongest single piece of evidence in this comparison, and it's why Zepbound leads our answer for plain adult weight loss in the population the trial studied.

Two things to keep in mind. An average is not a promise — individual results vary. And side effects, contraindications, treatment history, and what you can stay on matter too. That's a conversation for your clinician, not a ranking table.

What the trial did NOT show

SURMOUNT-5 did not compare Zepbound against Wegovy HD 7.2 mg or Wegovy tablets. Wegovy HD was studied separately and FDA approved in March 2026 for adult weight reduction.

But those are different trials, with different people, run at different times. Numbers from separate trials are not a head-to-head result. Anyone stacking them side by side to declare a proven winner is doing something the data doesn't support.

If your plan lists Wegovy HD and your clinician thinks it fits, that's a legitimate path. The direct trial above cannot tell you how Wegovy HD compares with Zepbound.

“Wegovy” is not one thing on your formulary

This is the mistake we'd most like to stop you from making.

There are three Wegovy paths in current FDA labeling:

• Standard Wegovy injection — weekly pens from 0.25 mg through 2.4 mg
• Wegovy HD injection — the 7.2 mg weekly dose for adults who tolerate 2.4 mg for at least four weeks and need more weight reduction, when the clinician decides it is appropriate
• Wegovy tablets — a daily adult pill that steps up to a 25 mg maintenance dose

They do not carry every same use:

So when you look up your coverage: do not stop at the word “Wegovy.” Find your exact strength and exact form. Same brand family, different products, different labeled uses, potentially different answers.

When Wegovy is the clearer path

Not “better.” Clearer, because the FDA label points at you specifically:

• You have established cardiovascular disease plus overweight or obesity. Standard Wegovy injection and Wegovy tablets carry a labeled cardiovascular risk-reduction use. Zepbound does not.
• You have noncirrhotic MASH with F2 to F3 fibrosis. Standard Wegovy injection carries an accelerated-approval use there. This is not “any fatty liver.”
• You're 12 to 17 with obesity. Standard Wegovy injection carries a labeled use in that age group. Wegovy HD and Wegovy tablets do not.
• You want a daily tablet and the cardiovascular use fits you. Then Wegovy tablets enter the conversation.

When Zepbound is the clearer path

• Plain adult weight loss in the SURMOUNT-5 type of patient. The direct evidence favors tirzepatide over semaglutide 1.7 or 2.4 mg.
• Obesity plus moderate-to-severe obstructive sleep apnea. Zepbound carries a labeled use for that exact group. Wegovy does not.
• Your clinician looks at your history and prefers it. That outranks anything on this page.

### Check three Wegovy entries, not one Before your appointment, look up standard Wegovy injection, Wegovy HD 7.2 mg, and Wegovy tablets separately. Then look up Zepbound. Bring the exact tier, form, PA rule, deductible treatment, and exclusion result to your doctor.

What about the pills — Foundayo and the Wegovy tablet?

Foundayo is a once-daily FDA-approved weight-management pill for adults that can be taken with or without food. Wegovy tablets are also once daily for adults, but they must be taken on an empty stomach in the morning with no more than four ounces of water, followed by a wait of at least 30 minutes before food, drinks, or other oral medicines. One live SmithRx plan's August prior-authorization file names FOUNDAYO and WEGOVY, but the word WEGOVY alone does not tell us whether that plan means the injection, the tablet, or both.

Why current plan files matter for new products

Look at the timeline:

The live file has moved fast enough to name new products, but it still does not settle every coverage detail. The general WEGOVY entry is the proof: a current file can name a brand family without telling you whether the result means the injection, the tablet, or both.

Use the live member lookup and current plan files. If the result is vague, call and ask for the exact dosage form, strength, NDC if available, tier, PA status, and benefit status.

Foundayo versus Wegovy tablets

Both are FDA-approved for adult weight management. Both are daily tablets. The daily routine is different, and that matters when you decide what you can follow every day.

Easier to take does not mean medically better. It means the routine may fit your real mornings better. That's worth saying out loud to your clinician.

One thing to keep straight

Rybelsus and Ozempic tablets are daily semaglutide products for adults with type 2 diabetes, not FDA-approved weight-loss pills. The current FDA label gives specific switching pairs instead of equal milligram doses: Rybelsus 7 mg maps to Ozempic tablets 4 mg, and Rybelsus 14 mg maps to Ozempic tablets 9 mg. Both use an empty-stomach morning routine with up to four ounces of water and a 30-minute wait.

Wegovy tablets contain semaglutide too, but they sit in the weight-management lane and use different strengths. Same active ingredient does not mean the products, doses, labels, or coverage are interchangeable.

Does SmithRx cover Ozempic or Mounjaro for weight loss?

Ozempic and Mounjaro are type 2 diabetes brands. Neither is FDA-approved for weight loss. A clinician may prescribe a medicine off label, but an off-label prescription does not turn it into an FDA-approved weight-loss product and does not require a plan to cover it for that use. In the live Essential plan we checked, Mounjaro and Ozempic appear in the August prior-authorization and preventive files. The member's diagnosis and the plan's written criteria still control.

This confuses more people than any other question in the category, so here it is in one table.

Why it matters for your money, not just your paperwork:

• The current plan's preventive file names diabetes products such as Mounjaro, Ozempic, and Rybelsus. The weight-management brands were not located there.
• Plans can apply diagnosis and use criteria. An off-label prescription may be medically lawful, but the plan may still deny payment under its benefit rules.
• If you do have type 2 diabetes, the diabetes lane may be the right door because it matches the FDA-approved use and the condition in your chart.
• Age matters. Mounjaro is labeled for type 2 diabetes in adults and children age 10 and older. Ozempic tablets and Rybelsus are labeled for adults.

Do not ask anyone to change or misstate your diagnosis to get around a benefit rule. The request must match the prescription, the medical record, and the plan's criteria. If weight is your goal and the plan excludes weight-management drugs, jump to the cash-pay section instead.

Does SmithRx make you try other things first?

In one current Essential plan's standalone July 2026 step-therapy file, no GLP-1 product appears. That does not prove the prior-authorization criteria contain no earlier-treatment requirements. SmithRx's own Weight Management Program also says the program uses a rigorous, step-wise approach that puts lower-cost treatment and lifestyle management before GLP-1 medicine and requires a clinical review. The requirement can be real even when it is not printed in the standalone step file.

If you were told to try other things first while the drug file shows no GLP-1 step-therapy entry, you weren't necessarily lied to and the document isn't necessarily wrong. You may have been routed into a separate program adopted by your employer.

Where the step actually lives

SmithRx describes its Weight Management Program as a plan-sponsor option paired with virtual clinical providers. SmithRx says the program uses “strict gatekeeping,” a mandatory clinical review, and a step-wise path that puts lower-cost treatment and lifestyle management before GLP-1 medicine.

So there are two different gates, and they can look identical from the pharmacy counter:

A program requirement is not a SmithRx-wide rule for every member. It applies when the employer adopted that pathway. That's why two people with a SmithRx card can get different experiences.

The step-therapy inversion

Here's the detail we found genuinely surprising. In the current step-therapy file we checked, older diabetes products such as Janumet, Janumet XR, Januvia, saxagliptin, Steglujan, and Trijardy XR carry trial requirements. The GLP-1 products do not appear in that file.

That's the opposite of the usual story in the standalone step file. But absence from that file is not proof that the PA policy has no earlier-treatment rule. The current files show prior authorization on the GLP-1, while a separate weight-management program may add its own clinical sequence.

How to find out if your plan uses the program

Almost nobody prints this in the same place as the drug result. You have to ask, and the wording matters:

1. Call the member number on your card. Ask: “Does my plan require enrollment in a weight-management program before a GLP-1 will be covered? If yes, what is the program called?”
2. Ask HR or benefits: “Is a weight-management program part of our pharmacy benefit this plan year?”
3. If the answer is yes, ask the checklist in the denial section below before you enroll.

How to check your own SmithRx coverage in 10 minutes

Sign in to your SmithRx member account and search your exact brand, form, and strength under your own employer's plan. Then record more than yes-or-no: coverage, tier, copay or coinsurance, deductible treatment, prior authorization, step requirement, quantity limit, days supply, and any required pharmacy or program. Those fields, not a public article, produce your real answer.

This is the part that actually gets you unstuck. Ten minutes, five steps.

Step 1 — Make sure you're looking at the right plan

Sounds obvious. It's the number one source of wrong answers.

Check this if you changed employers this year, if your employer offers more than one plan option, if you switched plans at open enrollment, or if a spouse's plan is also in the picture. A formulary result from the wrong plan is worse than no result.

Step 2 — Search the exact brand and form

Not just “Wegovy.” Search these one at a time when they fit your question:

• Zepbound injection, including the exact device or vial listed on your prescription
• Standard Wegovy injection and the exact strength
• Wegovy HD 7.2 mg injection
• Wegovy tablets and the exact strength
• Foundayo tablets
• Ozempic injection (diabetes lane)
• Ozempic tablets (diabetes lane)
• Rybelsus tablets (diabetes lane)
• Mounjaro injection (diabetes lane)

If the portal returns only a brand name, call and ask the rep to confirm the dosage form and strength tied to the result.

Step 3 — Write down every field

Print this or copy it into your notes. Fill it in as you go.

Every field can change the answer. That's why “is it covered?” is the wrong final question and “what are all ten fields?” is the right one.

Step 4 — Check the benefit document, not just the portal

The portal is where you start. Your controlling benefit documents are where disputes get settled. Go find them — often under Documents in your benefits account — if any of these are true:

• The portal says the drug is listed but the pharmacy rejected it
• Weight-loss drugs look excluded
• You recently changed jobs or plans
• You're being pointed toward a different program
• The portal and a phone rep disagree
• The lookup shows a tier but not whether the drug category is an included benefit

Step 5 — Save proof

Every time. Date, screenshot or PDF, exact drug and form, plan year, the rep's name and a reference number if you called, and any prior authorization or denial number.

This isn't paranoia. An appeal is easier when you can show what you were told and when.

Never post a screenshot with your name, member ID, prescription number, claim number, or diagnosis anywhere public.

### Turn the result into an action plan Mark the ten fields above. Then use the denial table below to choose the next step. For a provider path based on your state, insurance, preferred form, and budget, use Find My GLP-1 Path.

What will a GLP-1 actually cost with SmithRx?

There is no single SmithRx price. Two real 2026 SmithRx client documents prove it. Sana publishes a $30 retail Tier 2 copay on its PPO plans. Cass County publishes $25 for a one-month Tier 2 fill on its copay plan. If your exact GLP-1 is covered and placed on Tier 2, your price can still differ because the employer plan sets the cost-sharing rules.

Let's be precise, because this is money.

Those are real examples, not your number. They show why even the same tier label does not produce one universal SmithRx copay.

Copay versus coinsurance — know which one you have

If your plan uses coinsurance on brand drugs, a preferred-brand tier may still be expensive. Find out which cost rule you have before you budget.

The other three things that move the number

Your deductible. Before you meet it, some plans make you pay the full allowed cost. Other plans cover certain preventive medicine first. Some plans have a separate pharmacy deductible. Ask which rule applies to the exact drug.

Days supply. A one-month and three-month fill can use different math. On the Sana example, mail order costs twice as much but supplies three months. That does not mean every plan or GLP-1 permits a 90-day fill.

Quantity limits. A quantity limit caps how much the plan will cover in a set period. We did not retrieve a current drug-specific quantity-limit table that we can safely publish, so we are not making up a number. Ask for the exact limit, days supply, and refill timing for your product.

About savings cards

A manufacturer savings card can lower what an eligible person pays, but it is not coverage. Three rules:

1. A savings card does not turn an excluded drug into a covered benefit. Some manufacturer programs may still offer a different cash discount to eligible commercially insured patients, so read the exact current terms.
2. Terms, dose prices, eligibility, and expiration dates change. Check the manufacturer's own current page, not an old blog.
3. Federal health program beneficiaries — including Medicare and Medicaid members — are generally not eligible for commercial manufacturer copay cards. Read the card terms for the exact exclusion list.

What prior authorization does SmithRx require, and how long does it take?

The answer is plan-specific. In one live Essential plan's August 2026 prior-authorization file, Foundayo, Wegovy, Wegovy HD, Zepbound, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, and liraglutide are among the named drugs. Soliqua and Xultophy were not located in that file. A separate SmithRx client page says urgent requests may take up to 72 hours and standard requests may take up to 15 days. That timeline is a real client example, not a promise for every plan.

If you're switching plans on January 1 or starting a new prescription, start the paperwork early. Ask your own plan for its deadline and the current written criteria.

Three rules that get mixed up constantly

They're different problems with different fixes. Knowing which one you hit saves time.

Who decides, and why that matters

Sana's SmithRx client page says prior authorization is handled by the SmithRx Clinical Team. It also says SmithRx uses a Pharmacy and Therapeutics Committee and a Value Assessment Committee when it evaluates drugs for formulary placement, weighing safety, efficacy, and cost-effectiveness.

That does not tell you the criteria for your request. The written policy for your exact plan and product is the document your prescriber's office needs.

What your doctor will likely need to document

The plan's current criteria control this, not our list. A request may ask for:

• Your diagnosis and the matching code
• Height, weight, or BMI where the policy requires it
• Related conditions
• What you've already tried
• Any reason another option will not work for you
• Why the specific drug fits the requested use
• Records required by a separate weight-management program

One request that saves time: ask SmithRx for the written criteria for your exact drug before your doctor submits. Then have the office answer each criterion by name, in order. Missing items can delay or sink a request.

What to do if SmithRx denies or excludes it

A denial and an exclusion are two different problems. A denial means the plan did not approve the request as submitted — that may be fixable. An exclusion means the employer plan does not include that benefit or category. An appeal can challenge how the plan applied its terms, but it cannot quietly add a benefit the plan document truly excludes. Get the exact reason in writing before you do anything else.

Step one: find out which one you're dealing with

Call and ask this exact question: “Is this a prior-authorization denial, a step or program requirement, a non-preferred or non-formulary status, or a benefit exclusion?”

Those words mean different things:

If information was missing

1. Ask exactly which item is missing.
2. Get the reference number.
3. Hand both to your prescriber's office.
4. Confirm they resubmitted, and get the date.
5. Ask when the status should update.

If it's a step requirement

Ask for the current written criteria. Then ask your clinician whether your existing history already satisfies them — a lot of people have already tried what the plan is asking about and just never documented it in the request.

Do not invent a failed treatment. The request must match your real medical record. A false answer can sink the request and damage the trust you need with your prescriber.

If it's a true exclusion

We'll be straight with you. An ordinary prior-authorization appeal cannot create a weight-management benefit that the controlling plan document excludes. First confirm that the exclusion is real and that the plan applied it to the right person, product, plan year, and benefit.

Your actual levers:

• The plan's formal appeal or grievance route if you believe the exclusion was applied incorrectly
• HR or benefits if the employer controls the plan design
• Open enrollment if another available plan includes the benefit
• A cash-pay FDA-approved path after you compare its full cost with your plan price

If you're pointed toward a program

Before you enroll, ask these eight questions. Neutral checklist, no spin:

1. Is the program required for coverage, or optional?
2. Who writes the prescription — the program's clinician or mine?
3. Are visits included, or billed separately?
4. Is the medication included in the program cost?
5. What happens to my current doctor relationship?
6. What happens if I'm already on a GLP-1?
7. What health data gets shared, and with whom?
8. What's the appeal process if the program says no?

If you believe the decision is wrong

1. Get the denial notice in writing.
2. Find the exact criterion or plan term it cites.
3. Compare it with what was actually submitted.
4. Ask your clinician for a response that addresses that specific criterion — not a general letter of support.
5. Follow the plan's appeal steps and deadline. Deadlines are real.
6. Keep copies of everything and every reference number.
7. If the issue is plan design rather than medical documentation, escalate to HR or benefits as well as using any formal plan route.

For the paperwork itself, see our GLP-1 formulary exception guide and GLP-1 insurance appeal guide.

If your plan won't cover a weight-loss GLP-1, what actually works?

When your employer plan truly excludes weight-management medicine, a cash-pay FDA-approved path is one real option. If you do not submit the prescription through insurance, there is no insurance prior authorization to approve. You still need a prescription, a clinician who says the drug fits, and enough money for the membership, medicine, labs, and follow-up that apply.

We only recommend this after everything above, on purpose. Do not assume insurance or cash pay always wins. Compare the approved plan price, deductible, and coinsurance with the full cash price. A covered drug can still cost more before a deductible; a cash path can still cost far more over a year.

But if you've confirmed an exclusion, waiting on the same PA does not fix it. Here's the honest comparison.

Our pick: Ro

First, the part most sites won't tell you.

Ro cannot change what's on your SmithRx drug list or make an excluded benefit covered. Its free insurance checker also does not promise a check for every new GLP-1 form. Ro's current pricing page names Ozempic, Wegovy, and Zepbound autoinjector pens for the insurance check. It does not name Foundayo tablets, Wegovy tablets, or Zepbound KwikPen in that checker sentence.

If a coverage check on one of those other products is your priority, your prescriber's office plus SmithRx is the better call, not us and not Ro. We earn nothing telling you that. We're telling you anyway.

But once you have confirmed a true exclusion and decide not to bill insurance, Ro can put the clinician, prescription path, support, and current brand cash options in one place.

What Ro states on its own pricing page, verified August 17, 2026:

Prices are not one flat price for the whole treatment. Starting-dose offers, dose increases, manufacturer terms, and prepaid membership terms can move the monthly total. Recheck Ro's page before paying.

### Does this sound like your situation? Your plan truly excludes weight-management medicine, you have compared the full cash cost, and you want an FDA-approved path with care in one place. Check FDA-approved options on Ro → (sponsored affiliate link; opens in a new tab) The eligibility step is not a prescription or a promise that a drug is right for you.

The other route worth checking: Sesame

Ro is not the only reasonable cash-pay path. Success by Sesame is the better first look if choosing your clinician and having video visits matter more than Ro's online intake-and-review model. Sesame says its care program starts at $59 per month with a 12-month commitment; medication is separate, and individual providers may charge more. Its current cash menu includes Foundayo, Wegovy tablets, Wegovy pens, and Zepbound forms.

The catch: Sesame says included lab costs apply through Quest Diagnostics and do not apply in Arizona, Hawaii, North Dakota, New Jersey, New York, Oklahoma, Rhode Island, South Dakota, or Wyoming. Recheck the care price, medication price, lab rule, and state availability before paying.

Compare FDA-approved options on Sesame → (provider site)

Who should not do this

Don't go cash-pay before you compare your real plan price. A copay may win. A high deductible or large coinsurance may not. Use the actual numbers.

Don't go cash-pay if you have type 2 diabetes and haven't checked the diabetes lane yet. A diabetes product may match your diagnosis and appear on your plan's preventive list.

Don't go cash-pay before you've confirmed the exclusion in writing. A missing PA item and a true exclusion are not the same problem.

One thing we will not do on this page

We are not putting compounded GLP-1 programs into this comparison. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before marketing. Mixing them into a page about FDA-approved products and employer-plan files would blur two different decisions. If that is the path you are researching, read our separate compounded GLP-1 guide.

What to ask SmithRx, your doctor, and HR

Three different people control three different pieces of this. SmithRx explains the pharmacy result and handles plan processes. Your clinician decides what's medically right and supports the paperwork. Your employer or plan sponsor controls much of the benefit design. Asking each one the right question is how you stop making the same call four times.

Copy these. Change the brackets. Done.

Ask SmithRx

“I'm enrolled in [employer name], plan [plan name or letter]. For [exact drug, dosage form, and strength], please confirm: whether the benefit is covered, tier, copay or coinsurance, how it applies to my deductible, preventive status, prior authorization, step or program requirements, quantity limit, days supply, and required pharmacy. If it is not covered, is that because it is non-preferred, non-formulary, excluded from my plan, not covered for my diagnosis, or tied to a separate program? Please give me a reference number for this call.”

Ask your clinician

“My SmithRx plan shows [paste your fields]. Based on my diagnosis, age, history, and the FDA-approved uses, which covered option fits me best? If prior authorization is required, what written criteria does the plan use, and does my chart address each item?”

Ask HR or benefits

“Is weight-management medicine excluded by our plan design, or is this a drug-specific authorization issue? Which plan document states the rule? Did it change for this plan year? Is a weight-management program required?”

The one-page appointment sheet

Bring this. Fill in the left column before you go, the right column during the visit.

### Still not sure which door is yours? Coverage, exclusion, program, and cash pay are four very different paths. Answer a few questions about your state, plan, preferred form, and whether you want FDA-approved or compounded treatment. Get your personalized action plan with Find My GLP-1 Path → Free. About two minutes. You get a shortlist with source-verified pricing and the right questions to ask.

How we researched this page

We used plan documents for benefit rules, current FDA labeling for approved uses, and a direct head-to-head trial for the comparative claim. Editorial conclusions are stated as first questions to ask — never as prescriptions or coverage promises.

Our source order

1. Current FDA labeling and FDA approval records — for approved use, age, form, dosing instructions, and approval dates
2. Current plan-specific SmithRx files — for what one live employer plan's PA, preventive, and step-therapy files name
3. SmithRx's own pages and current client materials — for PREV markings, member access, and the separate Weight Management Program
4. Peer-reviewed head-to-head trial evidence — for the Zepbound-versus-standard-Wegovy comparison
5. IRS guidance — for what an HDHP may treat as preventive care
6. Employer plan documents — clearly labeled as examples, never as every member's price
7. Official provider pricing pages — checked and dated
8. Forums and social posts — only to understand how people describe the problem, never as evidence about coverage, safety, price, or results

What we did not do

• We did not fabricate a member testimonial, rating, star score, author, credential, or medical reviewer.
• We did not stack numbers from separate trials to declare a winner.
• We did not publish an exact row count or universal tier we could not independently verify.
• We did not call a drug “clinically superior” outside the population and doses tested directly.
• We did not treat the word “WEGOVY” in a plan file as proof that every Wegovy form is covered.
• We did not publish quantity-limit figures or PA criteria we could not verify.
• We did not republish a SmithRx file that carries a no-duplicate notice.
• We did not score the medicines with the RX Index Score. That framework rates providers on clinical legitimacy, care quality, transparency, access, and cost. Drugs get described by FDA-labeled use, evidence, and plan access.

Who made this and why

Who: The RX Index Editorial Team, the organization byline used under named editorial oversight. There is no medical reviewer on this page, and we're not going to pretend there is one.

How: by comparing live August plan files, current FDA labels, two employer plan examples, federal tax guidance, the published head-to-head trial, and current provider pricing.

Why: because public answers often collapse “listed,” “covered,” “preferred,” “preventive,” and “cheap” into one word. They are five different questions.

Corrections: if you find an error, tell us and we'll fix it and date the fix. We're not hiding behind a “content may change” disclaimer.

Frequently asked questions

Does SmithRx cover Zepbound?

Zepbound is named in one live SmithRx Essential plan's prior-authorization file effective August 2026. That proves the drug is in that plan's PA file, not that every SmithRx plan covers weight-management medicine. Check your member portal and benefit document for Zepbound's exact form, tier, PA rule, deductible treatment, and any category exclusion.

Does SmithRx cover Wegovy?

“WEGOVY” and “WEGOVY HD” are named separately in one live plan's August prior-authorization file. Current FDA labeling also includes Wegovy tablets. The plan file does not tell us whether the plain “WEGOVY” entry covers the standard injection, tablet, or both. Search the exact form and strength in your own plan.

What tier is Wegovy on the SmithRx formulary?

There is no SmithRx-wide public tier we can safely quote for every Wegovy form and employer plan. One employer's PA file names WEGOVY and WEGOVY HD, but a PA-file entry does not state your tier. Search the exact form and strength in your own live lookup or member portal.

What does PREV mean on a SmithRx formulary?

PREV is a formulary marking for a preventive medicine in the SmithRx client materials we verified. One live plan also publishes a separate preventive-medication file. A PREV marking or preventive listing may let an HDHP cover a medicine before the deductible, but the benefit document and SmithRx Connect footnote can change how the list applies.

Why is my GLP-1 full price if it appears in the lookup?

Common reasons are a benefit exclusion, an unmet deductible, coinsurance instead of a flat copay, a missing prior authorization, or a required program. Cass County's document says its lookup does not answer whether a drug benefit category is covered. Sana says a listed weight-loss drug may still be excluded by the plan.

Does SmithRx require step therapy for GLP-1s?

No GLP-1 was located in the standalone July 2026 step-therapy file for the live Essential plan we checked. That does not rule out earlier-treatment requirements inside a PA policy. SmithRx's separate Weight Management Program also describes a step-wise approach. Ask for the written PA criteria and whether your employer adopted the program instead of assuming either answer applies to every member.

How long does SmithRx prior authorization take?

One SmithRx client page says urgent requests may take up to 72 hours and standard requests may take up to 15 days. Ask your plan for the current timeline, get a reference number, and start early.

Does SmithRx cover Foundayo or the Wegovy pill?

Foundayo is named in one live plan's August PA file. “WEGOVY” is also named, but the file does not identify the form. That is not enough to promise coverage for Wegovy tablets. Search the exact tablet and strength in your member portal or ask the rep to confirm the dosage form.

Does SmithRx cover Ozempic for weight loss?

Ozempic is a type 2 diabetes product, not FDA-approved for weight loss. A clinician may prescribe it off label, but the plan does not have to cover that use. The live plan we checked lists Ozempic in its PA and preventive files; diagnosis and written criteria still control.

Is Mounjaro on the SmithRx formulary?

Mounjaro appears in the PA and preventive files for the live Essential plan we checked. It is FDA-approved to improve glycemic control in adults and children age 10 and older with type 2 diabetes. It is not the FDA-approved tirzepatide brand for weight management; that brand is Zepbound.

Is Zepbound proven better than Wegovy HD 7.2 mg?

No direct trial cited on this page compared them. SURMOUNT-5 compared tirzepatide with semaglutide at maximum tolerated doses of 1.7 or 2.4 mg and reported about 20.2% versus 13.7% average weight change at 72 weeks. Wegovy HD was studied separately. Separate trials do not prove a head-to-head winner.

Is SmithRx an insurance company?

SmithRx is a pharmacy benefit manager. Cass County describes SmithRx as the PBM that processes pharmacy claims for its 2026 plan. Your employer plan and benefit documents still determine covered categories and cost sharing.

Do all SmithRx members have to use a weight-management program?

No. SmithRx markets the program to plan sponsors. It applies when an employer adopts it. Ask your plan whether enrollment is required, what the program is called, who runs the clinical review, and what happens if you are already on treatment.

Does being on the formulary guarantee coverage?

No. A current SmithRx drug file says it does not guarantee coverage and that the benefit document may exclude listed drugs. Sana says the same thing, and Cass County says the lookup does not answer whether drug benefit categories are covered.

How often does SmithRx update its formulary?

Sana's SmithRx client page says formularies are updated quarterly. Use the live plan lookup and your member portal rather than treating a saved or printed copy as final.

Can I use HSA money for Zepbound?

A prescribed medicine can generally be a qualified medical expense for an HSA distribution. That is separate from whether your health plan pays before the deductible. Check your plan's deductible rule and current preventive file, and use current IRS guidance for tax questions.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

Related reading: Best GLP-1 for weight loss · GLP-1 formulary tiers explained · How to file a formulary exception · How to get insurance to cover a GLP-1

Sources

• SmithRx member resources and login
• SmithRx Weight Management Program
• SmithRx: what happens when a medication is not on the formulary
• Cass County 2026 plan Q&A, including its SmithRx Essential lookup and plan prices
• Cass County SmithRx Essential live drug lookup
• Cass County plan-specific prior-authorization list, effective August 2026
• Cass County plan-specific preventive-medication list, effective August 2026
• Cass County plan-specific step-therapy criteria, updated July 2026
• Sana Benefits: SmithRx formulary, plan prices, exclusions, PA timing, and quarterly updates
• Sana Benefits: accessing no-cost preventive medications and PREV/ACA markings
• FDA prescribing information: Zepbound
• FDA prescribing information: Wegovy injection, Wegovy HD, and Wegovy tablets
• FDA prescribing information: Foundayo
• FDA Foundayo approval announcement
• FDA Wegovy HD approval announcement
• FDA prescribing information: Mounjaro
• FDA prescribing information: Rybelsus and Ozempic tablets
• Current Ozempic injection label, DailyMed
• FDA prescribing information: Saxenda
• SURMOUNT-5 publication record
• IRS Notice 2019-45
• IRS Publication 969
• FDA: Compounding and the FDA — Questions and Answers
• Ro official weight-loss pricing
• Ro: how its online weight-loss program works
• Sesame official online weight-loss program, care model, pricing, and lab limits

Last verified: August 17, 2026. Version 2.0.